RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2019 to Q4 2025

Type / Class
Equity / Class A Common Stock, $0.00001 par value per share
Symbol
RXRX on Nasdaq
Shares outstanding
4,564,846
Price per share
$4.09
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
324,120,374
Total reported value
$1,581,610,307
% of total 13F portfolios
0%
Share change
+13,997,461
Value change
+$66,830,717
Number of holders
319
Price from insider filings
$4.09
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 8.5% $186,315,247 32,346,397 ARK Investment Management LLC 31 Dec 2024
BlackRock, Inc. 6.1% $134,995,023 23,436,636 BlackRock, Inc. 31 Dec 2024
RA CAPITAL MANAGEMENT, L.P. 2% $44,496,553 7,725,096 RA Capital Management, L.P. 31 Dec 2024
Kim Yohan 5.9% $1,540,800 267,500 Yohan Kim 04 Apr 2025

As of 30 Sep 2025, 319 institutional investors reported holding 324,120,374 shares of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX). This represents 7100% of the company’s total 4,564,846 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) together control 6241% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 871% 39,780,153 +10% 0% $194,127,147
ARK Investment Management LLC 735% 33,545,499 +1.7% 0.97% $163,702,036
BlackRock, Inc. 695% 31,739,765 +12% 0% $154,890,053
BAILLIE GIFFORD & CO 525% 23,978,695 -0.81% 0.09% $117,016,031
STATE STREET CORP 400% 18,268,925 +63% 0% $89,152,354
SOFTBANK GROUP CORP. 321% 14,667,491 0% 0.28% $71,577,356
KINNEVIK AB (PUBL) 294% 13,434,171 0% 100% $65,558,755
Mubadala Investment Co PJSC 284% 12,985,927 0% 0.35% $63,371,324
MIC Capital Management UK LLP 211% 9,644,032 0% 9.4% $47,062,881
GEODE CAPITAL MANAGEMENT, LLC 211% 9,623,557 +24% 0% $46,971,473
NOVO HOLDINGS A/S 174% 7,929,835 -18% 2.5% $38,697,595
NVIDIA CORP 169% 7,706,363 0% 0.98% $37,607,051
Sumitomo Mitsui Trust Group, Inc. 164% 7,465,858 -8.6% 0.02% $36,433,387
Amova Asset Management Americas, Inc. 164% 7,465,858 -8.6% 0.35% $36,358,728
MORGAN STANLEY 160% 7,290,353 +28% 0% $35,576,930
Data Collective IV GP, LLC 130% 5,941,120 0% 43% $28,992,666
SUSQUEHANNA INTERNATIONAL GROUP, LLP 118% 5,389,176 +68% 0.04% $26,299,178
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 92% 4,196,978 -9.1% 0% $20,481,253
DCVC Opportunity Fund II GP, LLC 87% 3,951,141 0% 100% $19,281,568
UBS Group AG 82% 3,753,778 -19% 0% $18,318,437
Lingotto Investment Management LLP 81% 3,675,077 0% 0.34% $17,934,376
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 75% 3,445,020 +33% 0% $16,811,698
NORTHERN TRUST CORP 73% 3,337,296 +14% 0% $16,286,005
FMR LLC 71% 3,228,857 -42% 0% $15,756,823
TWO SIGMA INVESTMENTS, LP 54% 2,450,805 +110% 0.02% $11,959,928

Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 411,499 $1,707,248 -$291,319 $4.09 13
2025 Q3 324,120,374 $1,581,610,307 +$66,830,717 $4.88 319
2025 Q2 310,183,849 $1,569,493,350 +$26,510,414 $5.06 330
2025 Q1 304,244,163 $1,609,644,574 -$29,277,151 $5.29 330
2024 Q4 304,503,855 $2,058,469,618 +$292,132,014 $6.76 310
2024 Q3 260,820,186 $1,719,746,530 +$28,653,319 $6.59 263
2024 Q2 251,850,622 $1,888,683,928 +$322,791,585 $7.50 266
2024 Q1 209,510,354 $2,088,608,377 +$37,886,806 $9.97 242
2023 Q4 115,242 $1,161,411 -$1,944,462 $10.24 2
2023 Q3 148,724,178 $1,137,621,261 +$183,957,032 $7.65 186
2023 Q2 124,630,128 $930,882,315 -$5,481,231 $7.47 152
2023 Q1 126,120,204 $841,172,158 +$14,956,626 $6.67 156
2022 Q4 123,700,274 $953,734,795 +$134,757,439 $7.71 142
2022 Q3 111,822,482 $1,189,744,484 +$75,116,009 $10.64 137
2022 Q2 103,476,748 $842,301,497 +$96,426,074 $8.14 127
2022 Q1 94,846,153 $678,702,525 -$13,110,736 $7.16 119
2021 Q4 93,345,592 $1,599,320,942 +$283,166,441 $17.13 120
2021 Q3 54,885,134 $1,262,502,377 +$181,282,325 $23.01 82
2021 Q2 46,974,230 $1,714,334,294 +$1,714,333,177 $36.50 77
2021 Q1 30 $1,000 $0 $33.33 1
2020 Q4 30 $1,000 $0 $33.33 1
2020 Q3 30 $1,000 $0 $33.33 1
2020 Q2 30 $1,000 $0 $33.33 1
2020 Q1 30 $1,000 $0 $33.33 1
2019 Q4 30 $1,000 $0 $33.33 1
2019 Q3 30 $1,000 $0 $33.33 1
2019 Q2 30 $1,000 $0 $33.33 1
2019 Q1 30 $1,000 $0 $33.33 1